Jeffrey Wong
City of Hope Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jeffrey Wong as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:59 UTC. Open this list on ClinicalTrials.gov
- N/ANCT02293954 · Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive CancerCity of Hope Medical Center · active not recruiting · Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer · principal investigator
- Ph2NCT01320683 · Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal CancerCity of Hope Medical Center · terminated · Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer · principal investigator
- Ph1NCT01205022 · Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal CancerCity of Hope Medical Center · completed · Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer · principal investigator
- Ph1/Ph2NCT00645710 · Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With SurgeryCity of Hope Medical Center · completed · Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Anti-CD38 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Myelogenous LeukemiaR01CA292596 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2025 to 2026 · $738,698 awarded in 2026Same name and institution; not confirmed by an ID
- Targeted radiation and immunocytokine therapy for CEA positive malignanciesR01CA283603 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2023 to 2026 · $676,263 awarded in 2026Same name and institution; not confirmed by an ID
- Conformal Total Body and Marrow Irradiation for LeukemiaR01CA154491 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2020 to 2024 · $657,603 awarded in 2024Same name and institution; not confirmed by an ID
- Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute LeukemiaR21CA270912 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2022 to 2023 · $192,024 awarded in 2023Same name and institution; not confirmed by an ID
- Image-guided irradiation safely intensifies HSCT regimen for refractory leukemiaR01CA195519 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2016 to 2018 · $238,425 awarded in 2018Same name and institution; not confirmed by an ID
- Novel AHCT Regimen for Advanced Hodgkin Lymphoma using Y-90 anti-CD25 with BEAMR21CA185875 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2015 to 2016 · $174,122 awarded in 2016Same name and institution; not confirmed by an ID
- RADIOIMMUNOTHERAPY: CLINICAL STUDIESP01CA043904 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 1997 to 2011 · $140,555 awarded in 2011Grant number is on one of their registry trials
- INNOVATIVE IMMUNOIMAGING FOR PRESURGICAL CANCER STAGINGR01CA042329 · NCI · CITY OF HOPE NATIONAL MEDICAL CENTER · fiscal years 1991 to 1994 · $343,538 awarded in 1994Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in colorectal cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:59 UTC. The ranking covers the 200 most relevant of 20 PubMed records, and a shared surname and initials can bring in a namesake. All 20 on PubMed
- Endolaparoscopic approach vs conventional open surgery in the treatment of obstructing left-sided colon cancer: a randomized controlled trial.Arch Surg · 2009169 citationsRCR 6.3
- Hand-assisted laparoscopic versus open right colectomy: a randomized controlled trial.Ann Surg · 200772 citationsRCR 2.3
- A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.Clin Cancer Res · 200371 citationsRCR 1.8
- Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.Clin Cancer Res · 200469 citationsRCR 1.7
- Towards painless colonoscopy: a randomized controlled trial on carbon dioxide-insufflating colonoscopy.ANZ J Surg · 200854 citationsRCR 1.9
- 43 citationsRCR 1.0
- Hand-assisted laparoscopic versus total laparoscopic right colectomy: a randomized controlled trial.Colorectal Dis · 201230 citationsRCR 1.1
- Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial.Cancer Res · 199528 citationsRCR 0.8
- Risk Stratification and Shared Decision Making for Colorectal Cancer Screening: A Randomized Controlled Trial.Med Decis Making · 201627 citationsRCR 1.1
- A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies.Clin Cancer Res · 200926 citationsRCR 0.6